A balanced 1:1 dual agonist, built for the liver
Pemvidutide is a synthetic peptide developed by Altimmune, Inc. (Nasdaq: ALT), a Maryland-based clinical-stage biotech focused on peptide therapeutics for liver and cardiometabolic disease. The development code is ALT-801. Like survodutide, it's a GLP-1/glucagon dual receptor agonist — but Altimmune's design choices distinguish it. The receptor ratio is engineered to be balanced 1:1, where most competitors lean more heavily toward GLP-1 with the second receptor as accent. And the molecule incorporates Altimmune's EuPort half-life domain, proprietary technology that slows the rate of entry into circulation. The slow-absorption profile is intended to soften the peak plasma levels associated with GI adverse events — which has translated, in the published trials, into a tolerability profile with discontinuation rates lower than placebo in the IMPACT MASH data.
The development strategy is multi-indication. Pemvidutide is being run in parallel through obesity (MOMENTUM Phase 2 completed 2023), MASH (IMPACT Phase 2b completed late 2025, Phase 3 launching 2026), alcohol use disorder (RECLAIM Phase 2 underway), and alcohol-associated liver disease (Phase 2 launched Q3 2025). The AUD application is mechanistically novel — GLP-1 receptor activation modulates mesolimbic reward signalling, reducing alcohol craving in early clinical work, and the glucagon component addresses the hepatic fat that often accompanies heavy drinking. If the AUD programme delivers, pemvidutide becomes one of the few peptides with a credible addiction-medicine indication.
The FDA granted Breakthrough Therapy Designation for MASH in January 2026 following 48-week IMPACT data. BTD significantly accelerates the regulatory path — more frequent FDA interactions, rolling review, and priority review at submission. It's a stronger signal than Fast Track alone (which pemvidutide also holds for MASH and AUD). The 48-week IMPACT data was selected as "Best of EASL 2026" for the Barcelona EASL Congress.
1:1 GLP-1/glucagon — with a slow-release domain
Dual Mechanism — Four Design Choices
Key MOMENTUM Phase 2 obesity data (n=320, 48 weeks, doses 1.2 / 1.8 / 2.4 mg vs placebo): 15.6% weight loss at 2.4 mg, 11.2% at 1.8 mg, 10.3% at 1.2 mg, 2.2% placebo. Near-linear continued weight loss at the 2.4 mg dose at the end of treatment — no plateau. Over 30% of 2.4 mg subjects achieved ≥20% body weight reduction. MRI sub-study: 21.9% lean loss ratio with stronger preservation in subjects aged 60 and over. Robust reductions in BMI, triglycerides, LDL cholesterol, blood pressure, with no clinically meaningful heart rate increase.
Key IMPACT Phase 2b MASH data (48 weeks, 1.2 mg and 1.8 mg vs placebo, F2/F3 fibrosis patients): 34.5% fibrosis improvement without MASH worsening (ITT analysis). cT1 reductions: -124 ms at 1.2 mg, -140 ms at 1.8 mg vs -21 ms placebo (both doses p<0.0001). AI-based digital pathology showed statistically significant fibrosis reduction at 24 weeks. Weight loss of up to 6.2% at 24 weeks with continued progression to 48 weeks on 1.8 mg, no plateau. Favourable tolerability — discontinuation-for-AE rate lower than placebo.
How pemvidutide sits against the class: Semaglutide STEP-1 (68 wk): ~14.9% weight loss, no glucagon component, recently MASH-approved. Tirzepatide SURMOUNT-1 (72 wk): ~20.9% weight loss, GLP-1/GIP, no glucagon. Survodutide SYNCHRONIZE-1 (76 wk): 16.6%, GLP-1/glucagon, no BTD. Retatrutide Phase 2 (48 wk): 24.2%, GLP-1/GIP/glucagon triple. Pemvidutide MOMENTUM (48 wk): 15.6% with class-leading lean preservation. The pemvidutide differentiators are body composition, MASH Breakthrough Therapy designation, and the multi-indication scope (AUD, ALD).